Table 4.
Summary of baseline Candida spp. and susceptibility—mITT population
| Participants | Species | MIC (mg/L) | |||
|---|---|---|---|---|---|
| Manogepix | Anidulafungin | Fluconazole | Amphotericin B | ||
| 1 | C. parapsilosis | 0.008 | 4 | 0.25 | 4 |
| 2 | C. parapsilosis | 0.004 | 0.5 | 0.5 | 1 |
| 3 | C. glabrata | 0.03 | 0.03 | 4 | 1 |
| 4 | C. glabrata | 0.016 | 0.03 | 1 | 0.5 |
| 5 | C. parapsilosis | 0.016 | 2 | 0.5 | 0.5 |
| 6 | C. glabrata | 0.03 | 0.03 | 2 | 0.5 |
| 7 | C. glabrata | 0.016 | 0.25 | 1 | 2 |
| 8 | C. glabrata | 0.008 | 0.03 | 0.5 | 1 |
| 9 | C. glabrata | 0.008 | 0.03 | 0.5 | 1 |
| 10 | C. glabrata | 0.004 | 0.12 | 1 | 1 |
| 11 | C. glabrata | 0.008 | 0.06 | 2 | 1 |
| 12a |
C. dubliniensis and
C. glabrata |
0.004 0.004 |
0.016 0.12 |
0.12 1 |
1 1 |
| 13 | C. albicans | 0.004 | 0.016 | 0.12 | 0.5 |
| 14b | C. albicans | 0.008 | 0.016 | 0.12 | 0.5 |
| 15 | C. albicans | 0.008 | 0.03 | 0.12 | 4 |
| 16 | C. albicans | 0.008 | 0.03 | 2 | 2 |
| 17 | C. albicans | 0.002 | 0.03 | 0.12 | 2 |
| 18 | C. albicans | 0.004 | 0.016 | 0.12 | 0.5 |
| 19 | C. albicans | 0.004 | 0.016 | 0.12 | 0.5 |
| 20 |
C. albicans and
C. glabrata |
0.004 0.016 |
0.03 0.25 |
0.12 0.5 |
2 2 |
CLSI, Clinical and Laboratory Standards Institute; DRC, data review committee; EOT, end of treatment; ITT, intent-to-treat; MIC, minimum inhibitory concentration; spp., species.
Patient with recurrent candidaemia; recurrence (mycological) defined as a mycologically confirmed infection with the same baseline Candida spp. during the 4 weeks after the EOT.
Patient with clinical relapse; relapse (DRC assessment) defined as re-occurrence of Candida in blood culture, or from other infection sites, during the follow-up period, or diagnostic parameters indicative of recurrence or late spread of the Candida infection.